Submission of Written Information

In general, individuals or organizations wishing to provide written information for consideration by the Citizens' Health Care Working Group should submit information electronically to *citizenshealth@ahrq.gov*. The Working Group invites submissions on those topics to be addressed at the Working Group business meetings listed above. Since all electronic submissions will be posted on the Working Group web site, separate submissions by topic will facilitate review of ideas submitted on each topic by the Working Group and the public.

Dated: September 1, 2005.

Carolyn M. Clancy,

Director.

[FR Doc. 05–18389 Filed 9–13–05; 9:47 am]

BILLING CODE 4160–90–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Notice of Meetings

In accordance with section 10(d) of the Federal Advisory Committee Act as amended (5 U.S.C., Appendix 2), the Agency for Healthcare Research and Quality (AHRQ) announces meetings of scientific peer review groups. The subcommittees listed below are part of the Agency's Health Services Research Initial Review Group Committee.

The subcommittee meetings will be closed to the public in accordance with the Federal Advisory Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C. 552b(c)(6). Grant applications are to be reviewed and discussed at these meetings. These discussions are likely to involve information concerning individuals associated with the applications, including assessments of their personal qualifications to conduct their proposed projects. This information is exempt from mandatory disclosure under the above-cited statutes.

1. *Name of Subcommittee:* Health Care Research Training.

Date: September 22–23, 2005 (Open from 8 a.m. to 8:15 a.m. on September 22 and closed for remainder of the meeting).

2. *Name of Subcommittee:* Health Research Dissemination and Implementation.

Date: October 20–21, 2005 (Open from 8 a.m. to 8:15 a.m. on October 21 and closed for remainder of the meeting).

3. *Name of Subcommittee:* Health Systems Research.

Date: October 20–21, 2005 (Open from 8 a.m. to 8:15 a.m. on October 21 and closed for remainder of the meeting).

4. *Name of Subcommittee:* Health Care Technology and Decision Sciences.

Date: October 27–28, 2005 (Open from 8 a.m. to 8:15 a.m. on October 27 and closed for remainder of the meeting).

5. *Name of Subcommittee:* Health Care Quality and Effectiveness Research.

Date: October 27–28, 2005 (Open 8 a.m. to 8:15 a.m. on October 27 and closed for remainder of the meeting).

All the meetings above will take place at: Agency for Healthcare Research and Quality, John Eisenberg Conference Center, 540 Gaither Road, Rockville, Maryland 20850.

Contact Person: Anyone wishing to obtain a roster of members, agenda or minutes of the nonconfidential portions of the meetings should contact Mrs. Bonnie Campbell, Committee Management Officer, Office of Extramural Research, Education and Priority Populations, AHRQ, 540 Gaither Road, Suite 2000, Rockville, Maryland 20850, Telephone (301) 427–1554. Agenda items for these meetings are subject to change as priorities dictate.

Dated: September 1, 2005.

Carolyn M. Clancy,

Director.

[FR Doc. 05–18388 Filed 9–13–05; 9:47 am]

BILLING CODE 4160–90–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 04065–Supplement]

Increasing Teen Driving Safety

A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the intent to fund fiscal year (FY) 2005 supplemental funds for a cooperative agreement program to provide support and assistance to the Society for Advancement of Violence and Injury Research (SAVIR), for the development and implementation of an intervention to encourage teen driver compliance with (and parental endorsement of) Graduated Driver Licensing restrictions on drivers who have an intermediate license—the group for which crash risk is highest among all drivers.

B. Eligible Applicant

Assistance will be provided to SAVIR. SAVIR is being targeted because they are uniquely qualified to carry out this activity. This assistance will be delivered as a supplement to Program Announcement 04065. SAVIR was the only recipient of this award and the current supplement is consistent with the scope of the original announcement. Dr. Robert Foss, the Principal Investigator, is a leading expert in the field of Graduated Drivers Licensing (GDL) interventions and has recently conducted a similar study using the same methodology. Currently, no other individual is in a position to conduct and evaluate an enhanced enforcement intervention, which requires the development of specific materials on local GDL laws to inform police officers, teens, and families about the requirements and penalties for GDL infractions. Dr. Foss has already developed these tools and training methods. The time it would take for another investigator to accrue the knowledge required for this task and set up an intervention and evaluation plan would set the date of completion back considerably and possibly derail the project. This work is critical to supporting the research agenda and CDC's mission to reduce fatalities and injuries to teens from motor vehicle crashes. This activity is also instrumental in carrying forward the research-related goals of the Adolescent Trailblazer team.

C. Funding

Approximately $231,000 is available in FY 2005 to fund this award. It is expected that the award will begin on October 1, 2005 and will be made for a 12-month budget period with a project period of up to two years. Funding estimates may change.

D. Where To Obtain Additional Information

For general comments or questions about this announcement contact: Technical Information Management Section, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341–4146, Telephone—770–488–2700.

For technical questions about this program, contact: Arlene Greenspan, Project Officer, CDC, National Center for Injury Prevention and Control, 4770 Buford Highway NE., Mailstop K–63, Atlanta, GA 30341, Telephone—770–488–1279, fax—770–488–1317, e-mail—*aig0@cdc.gov*.

Dated: September 9, 2005.

William P. Nichols,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 05–18321 Filed 9–14–05; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2004N–0486]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Experimental Study of Health Claims on Food Packages

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Experimental Study of Health Claims on Food Packages'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Peggy Robbins, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of April 20, 2005 (70 FR 20568), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0565. The approval expires on August 31, 2008. A copy of the supporting statement for this information collection is available on the Internet at *http://www.fda.gov/ohrms/dockets*.

Dated: September 7, 2005.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 05–18283 Filed 9–14–05; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Cardiovascular and Renal Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on November 16, 2005, from 8 a.m. to 5 p.m.

Location: Food and Drug Administration, CDER Advisory Committee Conference Room, rm. 1066, 5630 Fishers Lane, Rockville, MD.

Contact Person: Cathy Groupe, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301–827–7001, e-mail: *GroupeC@cder.fda.gov*, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014512533. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss new drug application (NDA) 21–628, proposed trade name CERTICAN (everolimus) Tablets (0.25 milligrams (mg), 0.50 mg, 0.75 mg, and 1.0 mg), Novartis Pharmaceuticals Corporation, for the proposed indication of prophylaxis of rejection in heart transplantation. The background material will become available no later than the day before the meeting and will be posted on FDA's Web site at *http://www.fda.gov/ohrms/dockets/ac/acmenu.htm.* (Click on the year 2005 and scroll down to the heading Cardiovascular and Renal Drugs Advisory Committee.)

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by November 8, 2005. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before November 8, 2005, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Beverly O'Neil at 301–827–7001, at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: September 6, 2005.

Scott Gottlieb,

Deputy Commissioner for Policy.

[FR Doc. 05–18365 Filed 9–14–05; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Dental Products Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Dental Products Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on October 11, 2005, from 9:15 a.m. to 5:45 p.m., and on October 12, 2005, from 8 a.m. to 5 p.m.

Location: Hilton Washington DC North/Gaithersburg, Ballroom Salons A and B, 620 Perry Pkwy., Gaithersburg, MD.

Contact Person: Michael E. Adjodha, Center for Devices and Radiological Health (HFZ–480), Food and Drug